All In MedTech

Device Trial Radar · NCT07546617

In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy

In Vivo Imaging of Olfactory Epithelium in Humans With Olfactory Impairment Using Confocal Laser Endomicroscopy

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Apr 30, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center for Advancing Translational Sciences (NCATS)
First posted
Apr 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research is being done to better characterize the part of the nose that helps people smell. Currently, the only ways to study smell loss mostly rely on how people report it, rather than being able to see the underlying structures directly. In this study, the team will use a special microscope (Confocal Laser Endomicroscopy (CLE)), originally developed for brain tissue, to look at the part of the nose that helps to detects smell. The study team hopes to identify the tiny structures in that area and see how they might be different in people who have smell loss compared to those who do not. Participation in the study includes completing a smell test (Sniffin' Sticks Extended test), a cognitive screening test, and two questionnaires.

Conditions

  • Endonasal Surgery
  • Endoscopic Sinus Surgery
  • Olfactory Dysfunction

Interventions

  • CONVIVO systemDevice

    Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Following image acquisition, a pathologist present in the operating room, will review and capture each image.

  • Fluorescein injection, USP 10%Drug

    Sodium fluorescein will be administered intravenously or topically (applied directly to nasal mucosa) at doses of 5-10 mg/kg (not exceeding 20 mg/kg cumulative). Administration will be performed by the anesthesia team in the operating room.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the feasibility of in vivo CLE imaging of the olfactory cleft and nasal turbinate and determine whether CLE features correlate with validated psychophysical olfactory testing and patient-reported quality-of-life measures.Time frame: On day of Surgery, Day 0

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.